Intuitive’s venture capital arm launches second investment fund

2023-12-05
高管变更
Dive Brief:
Intuitive Surgical’s venture capital arm has launched a second investment fund with $150 million in new capital.
The Intuitive Ventures fund will support startups focused on improving healthcare access and coordination, developing precision diagnostics and interventions, and integrating digital technology, the firm said Monday.
The new fund follows the launch of Intuitive’s first venture capital fund three years ago and brings the firm’s total assets under management to $250 million.
Dive Insight:
The robotic surgery leader is among a number of large medtech companies to establish a venture capital operation dedicated to supporting a portfolio of early-stage companies. GE HealthCare, Johnson & Johnson and Boston Scientific have also launched venture funds.
The venture has since invested in more than 10 startups, supported by Intuitive Surgical's network and corporate oversight. Those companies include Capstan Medical, Endogenex, Flywheel, KelaHealth, MedCrypt, Neocis Optellum and Surge Therapeutics.
“Fund II deepens Intuitive's commitment to the broad ecosystem of innovators working to improve patient outcomes,” Intuitive Surgical CEO Gary Guthart said in a statement.
Intuitive Ventures Fund II will be led by Murielle Thinard McLane, who joined the firm earlier this year. Thinard McLane also takes over as managing partner and head of Intuitive Ventures from Oliver Keown, who has left the role to be CEO of a startup.
She previously was CEO of molecular diagnostics company Ontera and a co-founder of Nooma Bio, a life science tools platform. Before that, Thinard McLane was an executive in residence at GE HealthCare Ventures, where she helped launch Verana Health, a clinical database.
'
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。